Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 3 / 4 (development scale, not regulatory approval)
- Synonyms
- Tetrodotoxin; TTX; Tarichatoxin; Spheroidine; Maculotoxin; Araregai toxin; Tectin
- Note
- Not recorded
Clinical trials 6
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain
Pain · Cancer
Enrolment: 165 · Results not recorded
A Multicentre, Open-label, Long-term Efficacy and Safety Continuation Study of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Cancer-related Pain
Pain · Cancer
Enrolment: 113 · Results not recorded
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Chemotherapy-induced Neuropathic Pain · Chemotherapy-induced Peripheral Neuropathy
Enrolment: 35 · Results not recorded
A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Pain · Peripheral Neuropathy · Neuropathic Pain
Enrolment: 125 · Results not recorded
A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects
TQT Study
Enrolment: 25 · Results not recorded
Comparison of the Pharmacokinetics and Safety of Liquid (30 ug) and Lyophilized Tetrodotoxin (15 ug and 30 ug) Following Single and Twice Daily Subcutaneous Dose Administration to Healthy Volunteers
Healthy
Enrolment: 44 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatWoundSprague-DawleyMaleTopical ocularRepeated administration after corneal debridement
Model: Corneal epithelial debridement wound with repeated topical drug administration; corneal tactile sensitivity testing by Cochet-Bonnet esthesiometry
Adding dexmedetomidine to tetrodotoxin or saxitoxin significantly prolonged corneal anaesthesia beyond either drug alone, giving two to three times longer anaesthesia than proparacaine, whereas clonidine did not. The formulations were not cytotoxic and no test solution significantly delayed corneal…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
